Cowen Downgrades Regulus Therapeutics (RGLS) to Market Perform
Tweet
Share
E-mail
Get Alerts RGLS Hot Sheet
Price: $8.16 --0%
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 42
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 42
Join SI Premium – FREE
Cowen downgraded Regulus Therapeutics (NASDAQ: RGLS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $2.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Papa John\'s (PZZA) to Underperform, 'Management turnover increases NT uncertainty'
- Evercore ISI Downgrades Sun Life Financial (SLF) to In Line on YTD performance
- MasTec (MTZ) PT Raised to $470 at TD Cowen
Create E-mail Alert Related Categories
DowngradesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
